New Study Affirms Survival Rates for Localized Prostate Cancer Patients

A recent study published in the July 2025 issue of the *JNCCN—Journal of the National Comprehensive Cancer Network* indicates that patients diagnosed with localized prostate cancer who adhere to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines experience significantly high survival rates. Conducted in Sweden, the research analyzed data from 62,839 patients diagnosed between 2000 and 2020, categorizing them based on risk levels and treatment protocols.

According to Dr. Pietro Scilipoti, the lead researcher from Uppsala University in Sweden and IRCCS San Raffaele Hospital in Italy, the study found that 90% of patients with nonmetastatic low-risk prostate cancer are expected to survive well into their life expectancy when treated according to NCCN Guidelines. For those diagnosed with nonmetastatic higher-risk prostate cancer, the survival probability remains above 65%.

The data, gathered from the National Prostate Cancer Register (NPCR) of Sweden, highlighted that patients with low- and intermediate-risk cancers were six times more likely to die from other causes than from prostate cancer itself. Even patients categorized as high-risk had a twofold higher likelihood of dying from non-cancer-related issues.

In a statement, Dr. Scilipoti emphasized the importance of guideline adherence, stating, "If guideline-recommended treatment is used, most people with prostate cancer will live for many years after diagnosis. That includes active surveillance as an excellent treatment strategy for appropriately selected individuals."

The implications of this research extend beyond statistical survival rates. Dr. Ahmad Shabsigh, a member of the NCCN Guidelines Panel for Prostate Cancer and affiliated with The Ohio State University Comprehensive Cancer Center, remarked, "This study offers a big sigh of relief for many men facing a prostate cancer diagnosis. It reveals that with NCCN Guidelines-recommended treatment, you're significantly more likely to die from something else—up to six times more likely, in fact—even if your cancer is high-risk."

The study also presents a striking statistic: for patients with low-risk prostate cancer, many of whom are under active surveillance, the 30-year mortality risk attributable to the cancer itself is merely 11%. Dr. Shabsigh noted the importance of focusing on overall health rather than solely on cancer, underscoring the power of evidence-based treatment plans.

As evidenced by this research, the NCCN Guidelines have evolved into a critical resource for oncologists, providing transparent, evidence-based recommendations that shape treatment protocols worldwide. The NCCN, celebrating its 30th anniversary, remains dedicated to enhancing the quality of cancer care and prevention. The NCCN Guidelines for Patients, which are available at no cost, empower patients and caregivers with essential information for navigating treatment options.

This research not only reinforces the importance of adhering to established guidelines but also showcases the potential for long-term survival among localized prostate cancer patients, offering hope and reassurance to those affected by the disease. For more information, the full study can be accessed at JNCCN.org.